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Abstract. Background/Aim: Gut microbiota plays an
important role in colorectal cancer (CRC) and its composition
in CRC patients can be influenced by ethnicity and tumour
genomics. Herein, the aim was to study the possible
associations of ethnicity and gene mutations with the gut
microbiota in CRC patients. Materials and Methods: Bacterial
composition in stool samples of 83 CRC patients and 60
controls from Iran and Finland was studied by 16S rRNA gene
sequencing. The association of gut microbiota composition
with CRC, host mutations in KRAS, NRAS and TP53, and
ethnicity analysed. Results: Beta diversity analysis indicated
significant differences between the Iranian and Finnish gut
microbiota composition, in both controls and patients’ groups.
The Iranian controls had higher abundance of Prevotella and
lower abundance of Bacteroides compared to the Finnish
controls, while the Finnish patients had higher abundance of
Clostridium compared to Iranian patients. Abundance of
Ruminococcus was higher in patients compared to the controls.
Higher abundances of Herbaspirillum, Catenibacterium and
lower abundances of Barnesiella were associated with
mutations in NRAS, TP53, and RAS respectively. Conclusion:
A possible link of host gene mutations with gut bacterial
composition is suggested. 
The gut microbiota plays an integral role in the regulation of
different gastrointestinal functions. There is increasing
evidence that the gut microbiota not only contributes to the
initiation and progression of colorectal cancer (CRC) but
also influences the host response to cancer treatment,
especially chemo- and immunotherapy (1). In addition to its
regional effect in the gastrointestinal tract, the gut microbiota
also affects distant organs via its role in shaping the immune
system and host metabolism (2). Diet, lifestyle and ethnicity
are among the main determinants of microbiota composition,
and changes in diet associated with a modern lifestyle have
been linked to microbiota-mediated cancer risk (3). The host
genetic variation is also known to effect bacterial
composition (4), although this area has not been investigated
extensively. The host genetics is reported to strongly
influence the abundance of gut Christensenellaceae (5), the
bacteria associated with low body mass index. The
Bifidobacterium abundance has been linked with a variation
in the lactose tolerance gene LCT loci (6, 7). On the other
hand, tumour genome is reported to be a factor modulating
colonization of certain bacteria around colorectal tumour
tissue (8, 9). A high abundance of Fusobacterium has been
reported to be associated with CpG island methylator
phenotype (CIMP), microsatellite instability (MSI) and
mutations in CHD7/8 (10). However, the associations
between tumour mutations and gut microbiota composition
remain poorly understood.
The association of the gut microbiota composition with
different disease states makes them useful as potential
diagnostic markers of health and disease (11). Recent large-
scale studies have however demonstrated that ethnicity (12)
and geography (13) are strong independent factors explaining
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inter-individual differences in microbiota composition, even
more so than either diet or metabolic disease. It is therefore
important that associations of gut microbiota with serious
diseases, like cancer, should be tested in different
populations. We have earlier described an association of gut
microbiota with different types of gastrointestinal neoplasms
in Finnish patients (14). In the present study, the gut
microbiota composition of Iranian CRC patients and controls
were studied and compared to that seen among Finnish CRC
patients and controls to find bacterial profile related to
ethnicity and that related to CRC. We also compared
bacterial composition in CRC patients with and without host
gene mutations in KRAS, NRAS, HRAS and TP53 to examine
the possible associations between gut microbiota and cancer
gene mutations.
Materials and Methods
Patients and sample collection. Informed consent was obtained from
all Iranian and Finnish patients and controls before collection of
stool samples. The ethical permission (351/13/03/02/2014) for the
study was obtained from the Hospital District of Helsinki and
Uusimaa (HUS) review board.
All of the Iranian samples were collected in Isfahan University-
Alzahra Hospital (Isfahan, Iran) from CRC patients (IrCRC) and
controls (IrC) living in the Isfahan province located in the central
part of Iran. The stool samples were collected from 52 patients
diagnosed with CRC before starting any cancer treatment and 47
control samples from individuals who had undergone colonoscopy
due to some gastrointestinal symptoms but had normal findings on
colonoscopy (Table I). Among the CRC patients, 11 had rectal cancer
and 41 had colon cancer. Both the patients and controls were mainly
Muslims, following Iranian dietary habits and did not consume either
pork or alcohol. Sixteen percent of the patients and 9% of the
controls were smokers. All samples were collected between July,
2016 and December 2017. Specimens were collected in the hospital
and immediately stored at -80˚C until DNA extraction. 
Stool samples were also collected from 31 Finnish CRC patients
(HefeCRC) between April 2015 to May 2017, in Helsinki Uusimaa
Hospital District: Surgical, Meilahti, and Jorvi Hospitals in Finland.
Details of CRC patients and control group (HefeC) of Finnish origin
have been described previously (14). The Finnish patients and
controls followed mainly non-vegetarian diet, and on an average
week consumed 10-20 standard units of alcohol. Nearly thirty
percent of the Finnish patients and controls were smokers.
DNA extraction. From Iranian patients and controls, DNA was
extracted from stool samples (180-220 mg) using the QIAamp DNA
stool mini kit (Qiagen GmbH, Hidden, Germany) according to
manufacturer’s guidelines. DNA was quantified by Qubit 2.0
Fluorimeter (Thermo Fisher Scientific, Waltham, MA, USA) using
the Qubit dsDNA BR Assay Kit. Extracted DNA was stored
at –20˚C. DNA extraction from Finnish stool samples was
performed using PSP Spin Stool DNA Plus Kit (Stratec Molecular,
Berlin, Germany), as previously described (14).
The results of 16S rRNA gene sequencing from 31 Finnish CRC
patients and 13 healthy Finnish individuals published previously
(14) were used to compare results with those of Iranian cohort.
DNA samples of both Iranian and Finnish CRC patients and
controls were checked for quality and quantity by Qubit 2.0
Fluorimeter and all the analysis were done in the same laboratory,
by the same researchers in Helsinki, and following the same
methodological procedures, as previously described (14). 
Gene mutation analysis of host DNA from stool samples. Data
regarding hotspot mutations in KRAS, NRAS, HRAS, and TP53
genes in DNA from stool samples of Finnish patients was collected
from previously published results (15). Gene mutation information
was available for 79/83 CRC patients; TP53 mutations were seen in
13, NRAS in 6, KRAS in 3 and no mutations in HRAS patients (all
RAS mutations were found in 9 patients). DNA isolated from stool
samples of both Finnish and Iranian CRC patients were studied for
hotspot mutations in 22 cancer-related genes by targeted next
generation sequencing using Ion AmpliSeq Colon and Lung Cancer
panel v2 (Thermo Fisher Scientific, Waltham, MA, USA). DNA
samples were sequenced on Ion Personal Genome Machine System
(Thermo Fisher Scientific, Waltham, MA, USA) as previously
described (15).
16S rRNA gene sequencing. Library preparation, template
preparation and sequencing were performed on DNA isolated from
Iranian CRC and controls as described earlier for Finnish CRC and
control samples (14). For Finnish patients and controls, the results
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Table I. Characteristics of Iranian and Finnish colorectal cancer (CRC) patients and controls examined in this study. 
                                                                    Iranian CRC                           Finnish CRC                           Iranian controls                    Finnish controls
                                                                         (n=52)                                      (n=31)                                        (n=47)                                   (n=13)
Gender (Male/Female)                                     33/19                                        20/11                                          26/21                                      3/10
Age, years (mean±SD)                                 62.4±10.6                                 71.9±8.3                                    62.8±10.1                              44.2±13.6
Stage (Early/Late/Unknown)                          52/0/0                                      21/7/3                                                                                            
Location (Colon/ Rectum)                               41/11                                        12/19                                                                                             
Mutation (Yes/No)
  TP53                                                               10/40                                        3/26
  KRAS                                                               1/49                                          2/27
  NRAS                                                               6/44                                          0/29                                                
CRC, Colorectal cancer.
of 16S rRNA gene sequencing published earlier (14) were used for
comparison with Iranian samples and for examining the association
with gene mutations in DNA from stool samples. 
Briefly, sequencing libraries were prepared from 3 ng of DNA,
using Ion 16S Metagenomics kit (Thermo Fisher Scientific,
Waltham, MA, USA) according to the vendor’s instructions. Six
hypervariable regions (Primer set V2, V4, V8 and Primer set V3, V6-
7, V9) of 16S rRNA gene were amplified in two reactions/sample.
After PCR, the samples were end-repaired, purified with Agencourt®
AMPure® XP beads (Beckman Coulter, Brea, California, USA) and
ligated to barcoded sequencing adapters according to the kit protocol.
The libraries were quantified by the TapeStation (Agilent
Technologies, Santa Clara, CA, USA) and samples were diluted to
a 10 pM concentration.
The libraries were pooled and the template preparation was
performed with either Ion OneTouch 2 system using the Ion PGM™ Hi-
Q™ OT2 Kit (Thermo Fisher Scientific, Waltham, MA, USA) or Ion
Chef system using the Ion PGM™ Hi-Q™ Chef Kit (Thermo Fisher
Scientific, Waltham, MA, USA) following the kit protocols. The
OneTouch 2 or the Ion Chef was used for emulsion PCR and the quality
of resulting Ion Spheres were checked with Qubit 3.0 fluorometer
(Thermo Fisher Scientific, Waltham, MA, USA). Sequencing was
performed on the Ion PGM system using the Ion 318™ Chip (Thermo
Fisher Scientific, Waltham, MA, USA) and Ion PGM Hi-Q Sequencing
kit (Thermo Fisher Scientific, Waltham, MA, USA).
Data analysis. Operational taxonomic unit (OTU) tables were
created for the 16S rRNA gene sequencing data of a total of 143
stool samples. The samples were classified according to nationality
(Iranian/Finnish), cancer status (cancer/control), tumour location
(colon/rectum), tumour stage (early/late), and gene mutation status
of RAS (KRAS, NRAS, HRAS) and TP53. The between-sample
normalization was performed by rarefaction of the read counts to an
even depth and the rarefied read counts were converted into relative
abundances using the phyloseq R package (16). A total of 163 unique
genera were detected.
Alpha diversity and observed richness of the gut microbiota at
the genus level was analysed with the microbiome (17) and vegan
R packages (18). The Shannon index was used to estimate the
bacterial diversity, with community richness being quantified by the
number of unique taxa observed. Kruskal-Wallis test was applied to
test for the significance of group-level differences and correction
for multiple testing was performed for each group with the
Benjamini-Hochberg FDR method (19). 
Unsupervised principal coordinates analysis (PCoA), based on
Euclidean distance between Hellinger-transformed abundance
profiles (20) were performed with the phyloseq R package (16).
Only the genera that were detected in at least 20% of all samples
were included in the analysis. Community level differences
between the groups were tested with PERMANOVA for CLR-
transformed (centered log-ratio transformed) abundances (21) with
the R package compositions (22) to remove compositionality bias.
ANCOM was applied to assess the significance of the differences
in the abundance of the individual genera (23). 
Association of age and sex with taxa abundances was examined
by Spearman correlation and Wilcoxon test respectively, both
performed for CLR-transformed data in order to remove
compositionality bias. Since no significant association of age or sex
with taxa abundances was observed, we did not include these as
covariates in our analysis.
Results
The characteristics of the CRC patients and controls groups
included in the study are described in Table I.
Bacterial alpha-diversity. The most significant difference in
gut microbiota alpha-diversity (Shannon index) was
observed between the Iranian and the Finnish controls
(p=0.004). Finnish controls had a higher bacterial richness
than their Iranian counterparts (Figure 1A). However, no
difference in alpha-diversity was observed between the
Iranian and the Finnish CRC patients (p=1.0) (Figure1B);
between the Iranian CRC patients and controls (p=0.51); and
between Finnish CRC patients and controls (p=0.10). All p-
values have been corrected for multiple testing as described
in the Materials and Methods.
Bacterial beta-diversity. The beta diversity of gut microbiota
composition (Figure 2; Table II) indicated that the Iranian
controls were significantly different from the Finnish
controls (p=0.006), and the Iranian CRC patients were
significantly different from the Finnish CRC patients
(p=0.006), indicating a strong ethnic influence on the gut
microbiota composition. The CRC patients and controls were
not significantly different for either nationality (p>0.1). 
Bacterial genera with significant differences in relative
abundances in different group comparisons. Significant
differences were observed between the Iranian and Finnish
controls also in the relative abundance of many individual
genera (Table III). The most notable difference was the high
relative abundance of Prevotella in the Iranian controls
compared to the Finnish controls (Figure 3A). Other
significant genera [Bacteroides, Roseburia, (Ruminococcus),
Eubacterium, Faecalibacterium and Lactococcus] had higher
relative abundances in Finnish control samples compared to
the Iranian controls. On the other hand, a comparison of
Iranian and Finnish cancer patients showed significant
differences in the relative abundance of only Clostridium;
that had a higher abundance in the Finnish CRC patients as
compared to Iranian patients (Figure 3B). 
The CRC patients had a higher relative abundance of
Ruminococcus compared to healthy individuals, when
samples were not classified according to ethnicity. Higher
relative abundance of Ruminococcus and Bifidobacterium
was also seen in Iranian CRC patients compared to
Iranian controls. On the other hand, lower relative
abundance of Bifidobacterium, Phascolarctobacterium
and Lachnoclostridium was seen in Finnish CRC patients
compared to the Finnish controls (Table III). 
Association of host gene mutations and gut microbiota. CRC
patients with RAS (KRAS/NRAS) gene mutations in the DNA
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isolated from stool samples had lower abundance of
Barnesiella in comparison to those patients without RAS
gene mutation (Figure 3C; Table III). The relative abundance
of Herbaspirillum was higher in NRAS mutated (Figure 3D);
of Catenibacterium higher (Figure 3) and Blautia lower in
TP53 mutated patients compared to the patients with no
mutation in the corresponding genes (Table III).
Fusobacterium among CRC and controls. We observed
presence of Fusobacterium in 18.6% of the samples from
CRC patients, which was significantly (p=0.01; Fisher’s
exact test) higher compared to 3.3% among controls. 
Discussion
Composition of gut bacteria is affected by both environmental
and genetic factors. Diet, lifestyle, ethnicity, age, sex and host
genotype are among the main determinants of microbiota
composition and the changes in gut bacterial composition are
linked to microbiota-mediated cancer risk (24-27). We aimed
to study gut microbiota and host gene mutations in stool
samples from CRC patients and controls from Iran and
Finland, in order to see the associations of ethnicity, CRC and
cancer gene mutations on the gut microbiota. 
Primarily, a strong influence of ethnicity on the gut
bacterial composition was noted in beta-diversity analysis.
Significant differences were seen between the Iranian and
Finnish controls (p=0.006) and between the Iranian and
Finnish CRC patients (p=0.006), while the differences were
not significant between patients and controls from the same
ethnic group (Table II; Figure 2). Thus, ethnicity seems to
have a more significant effect on the overall community
composition than the CRC status. The differences in alpha
diversity were however significant only between healthy
controls of Iranian and Finnish origin and non-significant
between CRC patients of these ethnic groups (Figure 1).
Finnish controls had higher bacterial diversity and richness
(Figure 1A) than Iranian controls. Similar higher gut
microbiota alpha-diversity among individuals of north
European origin (Dutch) compared to individuals of Middle-
Eastern and African ethnic groups living in the same city
(Amsterdam) has been reported earlier (11). A higher
bacterial alpha diversity has also been associated with a
healthier metabolic state (28).
In the present study, the most striking difference observed
between the controls was the high abundance of Prevotella
in Iranian controls, whereas the levels of these genera were
very low in Finnish controls (Figure 3A, Table III). A
marked lower abundance of Prevotella has been similarly
reported in Dutch individuals as compared to the high
abundance found in Moroccans, Turks, and Ghanaians (12).
It therefore seems that individuals of north European descent
have a low Provetella abundance, while individuals from
Middle-Eastern and other neighbouring countries harbour
high amounts of these bacteria. Previous studies have
described presence of three enterotypes driven by Provetella,
Bacteroides and Ruminococcus (29). The higher abundance
of Bacteroides among Finnish controls and Provetella among
ANTICANCER RESEARCH 40: 1325-1334 (2020)
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Figure 1. Comparison of alpha diversity between the groups. (A) Iranian (IrC) and Finnish (HefeC) controls, and (B) Iranian (IrCRC) and Finnish
(HefeCRC) colorectal cancer (CRC) patients.
Iranian controls could be indicative of higher prevalence of
Bacteroides –driven enterotype among Finnish controls and
Provetella –driven enterotype among Iranian controls.
Moreover, the enterotype driven by Provetella is associated
with non-western or fibre-rich diet and enterotype driven by
Bacteroides is associated with animal protein and saturated
fat diet (30). 
Although many genera had differential abundance among
the controls of Iranian and Finnish origin, only Clostridium
showed significant difference in abundance among the CRC
patients of these two populations, with lower abundance
among Iranian CRC patients. The differential abundances of
the genera between Iranian and Finnish groups might have
been influenced by diet. The major differences in the dietary
habits between the two ethnic groups are the absence of pork
meat and alcohol intake among Iranian patients and controls.
Higher abundance of Clostridium (seen in Finnish CRC
patients) and higher abundance of Bacteroides (seen in
Finnish controls) has been previously associated with alcohol
consumption (31).
Gut bacterial dysbiosis is commonly seen in patients with
CRC. Although in literature there are discrepancies regarding
the bacterial profiles associated with CRC, higher abundance
of Fusobacterium is one of the most frequent observations
associated with CRC status (32, 33). In line with previous
studies, we observed significant differences (p=0.01) in the
presence of Fusobacterium among CRC patients and controls.
Fusobacterium has been found to be strongly associated with
CRC (32) and involved in metastasis of CRC (33).
In order to identify which bacteria were associated with
CRC, we compared the bacterial composition of all CRC
patients with all controls, irrespective of ethnicity. Only,
Ruminococcus, had a significantly higher abundance in
cancer patients compared to the controls, as well as in
Iranian CRC compared to Iranian controls. According to the
literature, Ruminococcus is able to break down resistant
starches in the gut and supply nutrients to the host and also
provides growth substrates for other bacteria (35).
Differential abundance of Ruminococcus has been previously
reported in CRC (34) and a recent study revealed higher
abundance of Ruminococcus in patients at stage-1 of CRC
compared to healthy individuals (36). Similarly, in our study,
all Iranian CRC patients and the majority of the Finnish
patients had early stage of cancer (Table I). Therefore, the
increased abundance of Ruminococcus might be associated
with early stages of CRC. 
The Finnish CRC had lower abundances of Bifidobacterium,
Phascolarctobacterium and Lachnoclostridium than their
healthy counterparts. Lower levels of both Phascolarcto-
bacterium and Lachnospiraceae NK4A136 have been related
to psychosocial stress in children (37). Bifidobacterium and
Phascolarctobacterium confer beneficial health properties, and
moreover, the presence of Phascolarctobacterium has been
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Table II. Group-level comparisons based on community composition.
Analysed for beta diversity differences among groups by PERMANOVA
with 999 permutations and Benjamini-Hochberg FDR correction for
multiple testing. The associations with FDR<0.25 (adjusted p-value)
are shown. 
Groups compared                                      R2                  Adj. p-Value
IrC and HefeC                                         0.151                     0.006
IrCRC and HefeCRC                              0.062                     0.006
IrC and IrCRC                                        0.025                     0.146
AllC and AllCRC                                    0.017                     0.158
HefeC and HefeCRC                              0.056                     0.146
Location (colon and rectum)                  0.021                     0.190
Stage (early and late)                              0.022                     0.191
IrC, Iranian controls; HefeC, Finnish controls; IrCRC, Iranian colorectal
cancer patients; HefeCRC, Finnish colorectal cancer patients; AllC, all
controls; AllCRC, all colorectal cancer patients; FDR, false discovery rate.
Table III. Genera which were significantly differentially abundant in the
group-wise comparisons (False discovery rate, FDR<0.25). The Log10
fold change estimates are based on centered log-ratio (CLR)-
transformed abundances between the group means.
Genus                                                                                            Log10
                                                                                                 fold-change
Finnish controls/Iranian controls                                                    
Prevotella                                                                                    –3.10
Bacteroides                                                                                   0.75
Roseburia                                                                                      0.71
[Ruminococcus]                                                                           0.68
Eubacterium                                                                                 0.55
Faecalibacterium                                                                         0.40
Lactococcus                                                                                  0.33
Finnish CRC patients/Iranian CRC patients                                  
Clostridium                                                                                    0.86
Iranian CRC patients/Iranian controls                                            
Bifidobacterium                                                                            0.86
Ruminococcus                                                                               0.77
Finnish CRC patients/Finnish controls                                          
Phascolarctobacterium                                                              –1.41
Bifidobacterium                                                                          –1.10
Lachnoclostridium                                                                      –0.89
All CRC patients/All controls                                                        
Ruminococcus                                                                               0.68
CRC patients with RAS mutation/no RAS mutation                       
Barnesiella                                                                                  –1.30
CRC patients with NRAS mutation/no NRAS mutation                  
Herbaspirillum                                                                             0.98
CRC patients with TP53 mutation/no TP53 mutation                   
Catenibacterium                                                                           0.99
Blautia                                                                                        –0.66
CRC, Colorectal cancer; RAS, RAS type GTPase family (gene group
including HRAS, NRAS and KRAS); NRAS, NRAS proto-oncogene,
GTPase; TP53, tumor protein p53.
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Figure 2. Comparison of community composition between groups based
on beta diversity. Redundancy analysis (RDA) showing community
variations in the different group comparisons: (A) Iranian controls (IrC)
and Finnish controls (HefeC), (B) The Iranian colorectal cancer
patients (IrCRC) and the Finnish colorectal cancer patients (HefeCRC),
(C) The Iranian controls (IrC) and the Iranian colorectal cancer
patients (IrCRC), (D) The Finnish controls (HefeC) and the Finnish
colorectal cancer patients (HefeCRC), and (E) All controls (AllC) and
all colorectal cancer (AllCRC) patients. 
associated with a positive mood in the host (38). The higher
abundances of these bacteria in Finnish controls might be
linked to a healthier state.
The most significant association of host gene mutations with
gut bacterial composition was a lower abundance of
Barnesiella in patients with RAS mutations and higher
abundance of Herbaspirillum in NRAS mutated patients
compared to patients without these gene mutations. TP53
mutated patients showed higher abundance of Catenibacterium
and lower abundance of Blautia compared to patients without
mutations in TP53 gene. Barnesiella has been reported to
protect against the colonization of the highly antibiotic –
resistant Enterococcus faecium bacterium by restricting the
growth of these pathogens (39). Importantly, Barnesiella has
been associated with an anti-cancer immune response; these
bacteria have been found to modulate the efficacy of the anti-
cancer immunomodulatory agent, cyclophosphamide (40), by
enhancing the Tc1 (cytotoxic T lymphocytes) and Th1 (T
helper cell) response and restoring the function of intra-tumoral
interferon gamma (IFN-γ)-producing T cells. Gene expression
analysis from The Cancer Genome Atlas and the KFSYSCC
(Koo Foundation Sun Yat-Sen Cancer Centre) data sets have
revealed a suppressed Th1-/cytotoxicity in KRAS mutant
colorectal cancer patients (41). The absence of Barnesiella in
RAS mutated patients in our study, might also be associated
with compromised tumour immune surveillance in these
patients which would promote the development of the tumour.
Higher urinary abundance of Herbaspirillum has been
linked to high risk of recurrence of bladder cancer (42). The
abundance of Catenibacterium, seen in TP53 mutated
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Figure 3. Bacterial genera showing greatest differences in abundances (centered log-transformed; CLR) for various group comparisons. (A) Iranian
controls (IrC) and Finnish controls (HefeC), (B) Iranian colorectal cancer patients (IrCRC) and Finnish colorectal cancer patients (HefeCRC), (C)
colorectal cancer patients with and without the RAS mutations, (D) colorectal cancer patients with and without the NRAS mutations, and (E)
colorectal cancer patients with and without the TP53 mutations.
patients, has been associated with animal fat diet (43) and
diet rich in red meat, while food containing trans-fatty acids
has been reported to be associated with TP53 mutations in
colon cancer (44).
Since age and gender are important factors affecting gut
microbiota composition, a limitation of our study is that the
Finnish controls were of relatively younger age than the
other groups (Table I). However, no significant association
of age and sex with the observed abundances was found in
our data. Moreover, the small number of patients with RAS
and TP53 mutations in our study did not allow drawing any
firm conclusions. A more in-depth study on larger number of
patients with RAS and TP53 mutations is warranted to
confirm the associations of bacterial genera with RAS and
TP53 mutations found in this study.
We found that ethnicity is more significantly associated
with gut microbiota composition than is the cancer status.
Therefore, our results suggest that bacterial markers
associated with cancer status should be further tested in
patients from different ethnic groups, in order to assess their
usefulness as cancer marker. Further studies on the
association of bacterial genera with RAS and TP53 gene
mutations could elucidate the role of gut microbiota in the
growth of mutated cells and moreover, the impact of cellular
pathways that are dysregulated in mutated cells on the
abundance of specific bacteria. This knowledge could be
useful in identifying new therapeutic approaches.
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